Vivo Bio Tech Closes Trading Window Before Q4 FY26 Results

Vivo Bio Tech Limited has announced that its trading window will be closed from April 1, 2026. This move aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal policies.

Purpose of the Restriction

The primary goal is to prevent any potential misuse of unpublished price-sensitive information. By restricting trading for insiders and designated persons, the company ensures fair market practices until its financial results are made public.

Company Background and Compliance History

Vivo Bio Tech, a Hyderabad-based Contract Research Organization (CRO) established in 1987, specializes in drug discovery and preclinical research services. Similar trading window closures have been observed in past years, such as before the Q4 FY24 results announcement. Grounded research indicates a consistent history of SEBI compliance, with no reported adverse actions against the company or its key personnel by regulatory bodies.

Trading Restrictions for Insiders

During this closed period, all company insiders, designated employees, and their immediate relatives are prohibited from buying or selling Vivo Bio Tech securities. This restriction remains in effect until 48 hours after the official announcement of the company's audited financial results for the fourth quarter and the full fiscal year ending March 31, 2026.

Industry Peers

Vivo Bio Tech operates in the biotechnology and contract research sector. Its listed peers in India include companies such as Biocon Ltd., known for biopharmaceuticals; Anthem Biosciences Ltd., which focuses on contract research and manufacturing; and Sai Life Sciences Ltd., a broader player in the sector.

Recent Financial Snapshot (Q3 FY26)

For the third quarter of fiscal year 2026, which ended December 31, 2025, Vivo Bio Tech reported revenue of ₹13.65 crore and a net profit of ₹1.25 crore.

Looking Ahead: Q4 Results and Guidance

Investors will be closely monitoring the upcoming announcement of Vivo Bio Tech's audited financial results for Q4 FY26. The date of this announcement will also signal when the trading window will reopen. Any commentary or forward-looking guidance accompanying the results will be key for understanding the company's future prospects.